Controlled/modified release dosage forms: terminology, release rate and dose, drug properties relevant to modified release formulation, potential advantages of modified formulations.
Controlled/modified drug delivery systems: ion-exchange resins, diffusion systems, dissolution systems, erodible systems and osmotic systems.
Osmotic controlled drug delivery systems: classification (one or two chambers), important formulation and technological aspects in the development of osmotic systems. Examples of dosage forms: L-OROS, OROS-CT, Duros.
Parenteral dosage forms: intramuscular injections and implants (Ocusert® and Progestasert®).
Dermal and transdermal drug delivery systems.
Cyclodextrins: classification, factors affecting inclusion complex formation, mechanisms of drug release from cyclodextrin complexes; pharmaceutical applications of cyclodextrins.
Drug Targeting: passive targeting, physical/chemical targeting, active targeting.
Drug delivery systems
Erythrocytes as drug carrier
Liposomes: lipid chemistry, effect of molecular shape on the structure of the amphiphilic aggregate, methods of liposome preparations; liposome classification; physicochemical characterization of liposome; liposome stability (physical, chemical and biological stabilities); interaction of liposomes with cells, pH-sensitive liposomes, temperature-sensitive liposomes; "Stealth” and sterically stabilized liposomes; immunoliposomes; liposome pharmacokinetics; application of liposomes as drug delivery systems (medical and cosmetic applications of liposomes in humans); technological characterization of liposomes, industrial manufacture of liposomes.
Non-phospholipid vesicular systems (Niosomes): surfactant chemistry; factors leading to niosome formation; niosome classification, physicochemical and technological characterization of niosome; niosome stability (chemical and biological stability); niosomes in drug delivery and targeting.
Microparticles and nanoparticles: preparation methods; physicochemical and technological characterization; long circulating nanoparticles; mucoadhesive nanoparticles (composition and mucoadhesion theories); pharmaceutical application of microparticles and nanoparticles.
Analytical methods and industrial application.
Stability and stabilization of drugs and dosage forms:
Physical and chemical factors affecting drug and dosage form degradation, kinetics (first and zero order) and product stability.
Manufacture (recombinant DNA technology), production and downstream processing of biotech products, formulation of biotech products.
Genetic Drugs (DNA and oligonucleotides):
Gene therapy; antisense and anti-gene therapy; molecular mechanisms of antisense and anti-gene drugs; design and synthesis of oligonucleotide; biological barriers to gene delivery.
DNA and the oligonucleotide delivery: viral and synthetic carriers (cationic lipids, cationic polymers and lipopolyplexes)